Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-09-10
1999-03-30
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 514921, 530324, 530350, 530829, 424529, 424534, A61K 3800, A61K 3514
Patent
active
058889779
ABSTRACT:
Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5245013 (1993-09-01), Ulevitch et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5420019 (1995-05-01), Theofan et al.
patent: 5439807 (1995-08-01), Grinna
patent: 5447913 (1995-09-01), Ammons et al.
patent: 5466580 (1995-11-01), White et al.
patent: 5466581 (1995-11-01), White et al.
patent: 5484705 (1996-01-01), White et al.
patent: 5488034 (1996-01-01), McGregor et al.
patent: 5494896 (1996-02-01), Hansbrough
patent: 5523288 (1996-06-01), Cohen et al.
patent: 5532216 (1996-07-01), Espevik et al.
patent: 5576292 (1996-11-01), Elsbach et al.
patent: 5578568 (1996-11-01), Ammons et al.
patent: 5578572 (1996-11-01), Horwitz et al.
Thornton et al., The FASEB Journal, vol. 8, No. 4, Mar. 15, 1994, Abstract No. 794, p. A137.
Marighe et al, Blood, vol. 85, No. 2. pp. 3437-3443, Jun. 15, 1995.
Marighe et al, The Journal of Infectious Diseases, vol. 172, pp. 144-151, Jul. 1995.
Ammons et al., "Recombinant Amino Terminal Fragment of Bactericidal/Permeability Increasing Protein Prevents Hemodynamic Responses to Endotoxin", Circulatory Shock, 41(3):176-184 (Nov., 1993).
Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Rodent Models of Gram-Negative Sepsis: Role of Bactericidal Properties," J. Infect. Dis., 170(6):1473-82 (Dec., 1994).
Ammons et al., "An N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein Protects against Hemodynamic and Metabolic Derangements in Rat Gram-Negative Sepsis," J. Endotoxin Res., 3(1):57-66 (1996).
Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Endotoxemia and Gram-Negative Sepsis," Novel Therapeutics Strategies in the Treatment of Sepsis, pp. 55-70 (1996).
Baggiolini et al., "Neutrophil-activating Peptide-1/Interleukin 8, a Novel Cytokine That Activates Neutrophils", J. Clin. Invest., 84:1045-1049 (Oct., 1989).
Barron, "Pathophysiology of Septic Shock and Implications for Therapy," Clinical Pharmacy, 12(11):829-845 (Nov., 1993).
Berry, L.N., "Introduction" in Handbook of Endotoxin, vol. 3, Cellular Biology of Endotoxin, Berry, L.N., (Ed.), Elsevier, Amsterdam, New York, Oxford, pp. xvii-xxi, (1985).
Binnema et al., "Quantitation of Urokinase Antigen in Plasma and Culture Media by Use of an Elisa," Thromb. Res, 43:569-577 (1986).
Bloom et al., "Serum Neopterin Levels Following Intravenous Endotoxin Administration to Normal Humans", Immunobiol., 181:317-323 (1990).
Boermeester et al., "Bactericidal/Permeability-Increasing Protein (BPI) Prevents Hemodynamic and Metabolic Derangements Following Partial Hepatectomy," Dutch Society of Gastroenterology Meeting, p. 84 (Oct. 7, 1993) (Abstract).
Boermeester et al., "A Prophylactic Approach towards Postoperative Endotoxemia," in Yearbook of Intensive Care and Emergency Medicine 1994, Vincent, J.L., (Ed.), Springer-Verlag, pp. 35-41 (1994).
Boermeester et al. "Endotoxin and Interleukin-1 Related Hepatic Inflammatory Response Promotes Liver Failure After Partial Hepatectomy," Hepatology, 22(5):1499-15006 (Nov., 1995).
Boermeester et al., "Liver Failure Induces a Systemic Inflammatory Response," Amer. J. Pathology, 147(5):1428-1440 (Nov., 1995).
Bone, R.C., "The Pathogenesis of Sepsis," Ann. Inter. Med., 115:457-469 (1991).
Bone et al., "Definitions for sepsis and organ failure", Critical Care Medicine, 20(6):724-726 (1992).
Boujoukos et al., "Detection of Interleukin-8 in Bronchoalveolar Lavage Without Alveolar Neutrophil Influx, Before and After Intravenous Endotoxin in Normal Humans", Am. Rev. Resp. Dis., 145(4):A441 (Apr., 1992) (Abstract).
Boujoukos et al., "Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration", J. Appl. Physiol., 74:3027-3033 (1993).
Bradley et al., "Hemodynamic Alterations in Normotensive and Hypertensive Subjects During the Pyrogenic Reaction", J. Clin. Invest., 24:749-758 (1945).
Brandtzaeg et al., "Plasma Endotoxin as a Predictor of Multiple Organ Failure and Death in Systemic Meningococcal Disease," J. Infect. Dis., 159(2):195-204 (Feb., 1989).
Brandtzaeg et al., "Plasminogen Activator Inhibitor 1 and 2, Alpha-2-Antiplasmin, Plasminogen, and Endotaxin Levels in Systemic Meningococcal Disease," Thrombosis Research, 57:271-278 (1990).
Brandtzaeg et al., "Meningococcal Endotoxin in Lethal Septic Shock Plasma Studied by Gas Chromatography, Mass-Spectrometry, Ultracentrifugation, and Electron Microscopy," J. Clin. Invest., 89:816-823 (Mar., 1992).
Brandtzaeg, P., "Pathogenesis of Meningococcal Infections," in Meningococcal Disease, K. Cartwright, Ed., John Wiley & Sons, Ltd. pp. 72-114 (1995).
Brigham et al., "Endotoxin and Lung Injury", Rev. Respir. Dis., 133:913-927 (1986).
Calandra et al., "Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-1, Interferon-.alpha., and Interferon-.gamma. in the Serum of Patients with Septic Shock", J. Infect. Diseases, 161:982-987 (May, 1990).
Calandra et al., "High Circulating Levels of Interleukin-6 in Patients with Septic Shock: Evolution During Sepsis, Prognostic Value, and Interplay with Other Cytokines", Am. J. Medicine, 91:23-29 (Jul., 1991).
Cannon et al., "Circulating Interleukin 1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever", J. Infect. Diseases, 161:79-84 (Jan., 1990).
Cavaillon, J.M., "Controversies Surrounding Current Therapies for Sepsis Syndrome," Bull. Inst. Pasteur., 93:21-41 (1995).
Chmielewska et al., "Evidence For a Rapid Inhibitor To Tissue Plasminogen Activation in plasma," Thromb. Res., 31:427-436 (1983).
Cochrane, "The Enhancement of Inflammatory Injury", Am. Rev. Respir. Dis., 136:1-2 (1980).
Colman, "Surface-mediated Defense Reactions, The Plasma Contact Activation System", J. Clin. Invest., 73:1249-1253 (May, 1984).
Cross et al., "Choice of Bacteria in Animal Models of Sepsis," Infect. Immun., 61(7):2741-2747 (Jul., 1993).
Cross, A.S., "Antiendotoxin Antibodies: A Dead End?" Ann. Intern. Med., 121(1):58-60 (Jul. 1, 1994).
Danner et al., "Endotoxemia in Human Septic Shock", Chest, 99:169-175 (Jan. 1991).
de Winter et al., "Recombinant Endotoxin-Binding Protein (rBPI.sub.23) Attenuates Endotoxin-Induced Circulatory Changes in Humans," J. Inflamm., 45:193-206 (1995).
De La Cadena et al., "Activation of the Kallikrein-Kinin System After Endotoxin Administration to Normal Human Volunteers", Blood, 81(12):3313-3317 (Jun. 15, 1993).
Dinarello, C.A., "The Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome", J. Infection Diseases, 163:1177-1184 (Jun., 1991).
Edwards et al., "Complications and Sequelae of Meningococcal Infections in Children," J. of Pediatrics, 99(4):540-545 (Oct., 1981).
Elin et al., "Effect of Induced Fever on Serum Iron and Ferritin Concentrations in Man", Blood, 49(1):147-153 (Jan., 1977).
Elms et al., "Measurement of Crosslinked Fibrin Degradation Products-An Immunoassay Using Monoclonal Antibodies," Thromb. Haemostas, 50(2):591-594 (1983).
Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability Increasing Protein and a Closely Associated Phospholipase A.sub.2 from Rabbit Polymorphonuclear Leukocytes," J. Biol. Chem., 254(21):11000-11009 (Nov., 1979).
Elsbach and Weiss, "Oxygen-Independent Antimicrobial Systems of Phagocytes," In Inflammation: Basic Principles and Clinical Correlates, Chapter 30, Second Edition, Gallin et al., (Eds.), Raven Press, Ltd., pp. 603-636, (1992).
Elsbach et al., "Prospects for Use of Recombinant BPI in the Treatment of Gram-Negative Bacterial Infections," Infect. Agents Dis., 4:102-109 (1995).
Evans et al., "Protective Effects of
Giroir Brett P.
Scannon Patrick J.
Mohamed Abdel A.
Tsang Cecilia J.
LandOfFree
Therapeutic uses of BPI protein products for human meningococcem does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of BPI protein products for human meningococcem, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of BPI protein products for human meningococcem will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1215102